OBJECTIVE: The objectives of this study were to (a) identify the patterns of disulfiram (Antabuse) and tablet naltrexone (Revia) adoption over a 48-month period in a nationally representative sample of privately funded programs that deliver substance use disorder treatment; (b) examine predictors of sustainability, later adoption, discontinuation, and nonadoption of disulfiram and tablet naltrexone; and (c) measure reasons for medication discontinuation. METHOD: Two waves of data were collected via face-to-face structured interviews with 223 program administrators. RESULTS: These data demonstrated that adoption of medications for alcohol use disorders (AUDs) was a dynamic process. Although nonadoption was the most common pattern, approximately 20% of programs sustained use of the AUD medications and 30% experienced organizational change in adoption over the study period. Bivariate multinomial logistic regression models revealed that organizational characteristics were associated with sustainability including location in a hospital setting, program size, accreditation, revenues from private insurance, referrals from the criminal justice system, number of medical staff, and use of selective serotonin reuptake inhibitors at baseline. Two patterns of discontinuation were found: Programs either discontinued use of all substance use disorder medications or replaced disulfiram/tablet naltrexone with a newer AUD medication. CONCLUSIONS: These findings suggest that adoption of AUD medications may be positively affected by pressure from accreditation bodies, partnering with primary care physicians, medication-specific training for medical staff, greater availability of resources to cover the costs associated with prescribing AUD medications, and amending criminal justice contracts to include support for AUD medication use.
OBJECTIVE: The objectives of this study were to (a) identify the patterns of disulfiram (Antabuse) and tablet naltrexone (Revia) adoption over a 48-month period in a nationally representative sample of privately funded programs that deliver substance use disorder treatment; (b) examine predictors of sustainability, later adoption, discontinuation, and nonadoption of disulfiram and tablet naltrexone; and (c) measure reasons for medication discontinuation. METHOD: Two waves of data were collected via face-to-face structured interviews with 223 program administrators. RESULTS: These data demonstrated that adoption of medications for alcohol use disorders (AUDs) was a dynamic process. Although nonadoption was the most common pattern, approximately 20% of programs sustained use of the AUD medications and 30% experienced organizational change in adoption over the study period. Bivariate multinomial logistic regression models revealed that organizational characteristics were associated with sustainability including location in a hospital setting, program size, accreditation, revenues from private insurance, referrals from the criminal justice system, number of medical staff, and use of selective serotonin reuptake inhibitors at baseline. Two patterns of discontinuation were found: Programs either discontinued use of all substance use disorder medications or replaced disulfiram/tablet naltrexone with a newer AUD medication. CONCLUSIONS: These findings suggest that adoption of AUD medications may be positively affected by pressure from accreditation bodies, partnering with primary care physicians, medication-specific training for medical staff, greater availability of resources to cover the costs associated with prescribing AUD medications, and amending criminal justice contracts to include support for AUD medication use.
Authors: Cindy Parks Thomas; Deborah W Garnick; Constance M Horgan; Frank McCorry; Amanda Gmyrek; Mady Chalk; David R Gastfriend; Suzanne Gelber Rinaldo; Joann Albright; Victor A Capoccia; Alex H S Harris; Henrick J Harwood; Pamela Greenberg; Tami L Mark; Huong Un; Marla Oros; Mark Stringer; James Thatcher Journal: J Subst Abuse Treat Date: 2010-10-08
Authors: Tami L Mark; Henry R Kranzler; Xue Song; Peace Bransberger; Virginia H Poole; Scott Crosse Journal: Addiction Date: 2003-05 Impact factor: 6.526
Authors: Andrea K Finlay; Ingrid Binswanger; Christine Timko; Joel Rosenthal; Sean Clark; Jessica Blue-Howells; Jim McGuire; Hildi Hagedorn; Jessie Wong; James Van Campen; Alex H S Harris Journal: Crim Justice Policy Rev Date: 2016-04-18